Last checked at 10 Sep 2015 07:00

Â
10 September 2015 |
Avacta Group plc
Â
("Avacta", the "Company" or the "Group")
Â
Total Voting Rights
Â
The Company would like to confirm that Avacta's issued share capital consists of 6,740,649,550 Ordinary Shares of 0.1p each with voting rights, and not 6,740,149,550 as was incorrectly stated in the Company's announcement on 3 September 2015.
Â
The above figure of 6,740,649,550 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules. The Company does not hold any shares in Treasury.
Â
- Ends -
Â
For further information:
Â
Avacta Group plc Tim Sykes, Chief Financial Officer | Tel: +44 (0) 844 414 0452 www.avacta.com |
 Numis Securities Limited Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking |  Tel: +44 (0) 207 260 1000 www.numiscorp.com |
 Media Enquiries FTI Consulting Simon Conway/Natalie Garland-Collins |  Tel: +44 (0) 20 3727 1000 avacta@fticonsulting.com |
Â
About Avacta Group plc - www.avacta.com
Â
Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through two divisions:
Â
Avacta Animal Health www.avactaanimalhealth.com | Veterinary diagnostics reference laboratory and diagnostic kit provider. Â |
Avacta Life Sciences www.avactalifesciences.com  | Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development. |
Â